[go: up one dir, main page]

DE69131449D1 - Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität - Google Patents

Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität

Info

Publication number
DE69131449D1
DE69131449D1 DE69131449T DE69131449T DE69131449D1 DE 69131449 D1 DE69131449 D1 DE 69131449D1 DE 69131449 T DE69131449 T DE 69131449T DE 69131449 T DE69131449 T DE 69131449T DE 69131449 D1 DE69131449 D1 DE 69131449D1
Authority
DE
Germany
Prior art keywords
exotoxins
improved
pseudomonas
animals
high cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131449T
Other languages
English (en)
Other versions
DE69131449T2 (de
Inventor
Ira Pastan
David Fitzgerald
Vijay Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Government of the United States of America
Original Assignee
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Government of the United States of America filed Critical US Department of Health and Human Services
Publication of DE69131449D1 publication Critical patent/DE69131449D1/de
Application granted granted Critical
Publication of DE69131449T2 publication Critical patent/DE69131449T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/874—Pseudomonas
    • Y10S435/875—Pseudomonas aeruginosa

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Motor Or Generator Frames (AREA)
DE69131449T 1990-05-11 1991-05-10 Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität Expired - Lifetime DE69131449T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52218290A 1990-05-11 1990-05-11
PCT/US1991/003238 WO1991018100A1 (en) 1990-05-11 1991-05-10 Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity

Publications (2)

Publication Number Publication Date
DE69131449D1 true DE69131449D1 (de) 1999-08-19
DE69131449T2 DE69131449T2 (de) 1999-11-25

Family

ID=24079787

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131449T Expired - Lifetime DE69131449T2 (de) 1990-05-11 1991-05-10 Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität

Country Status (9)

Country Link
US (2) US5512658A (de)
EP (1) EP0531434B1 (de)
JP (2) JP2665827B2 (de)
AT (1) ATE182175T1 (de)
AU (1) AU646673B2 (de)
CA (1) CA2082394C (de)
DE (1) DE69131449T2 (de)
DK (1) DK0531434T3 (de)
WO (1) WO1991018100A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
CA2271291A1 (en) 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Protease-activatable pseudomonas exotoxin a-like proproteins
AU5166698A (en) * 1996-11-08 1998-05-29 Emory University Method for treating certain pediatric acute leukemias
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
EP1000163B1 (de) * 1997-07-11 2005-10-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services Pseudomonas exotoxin-a-ähnliche chimerische immunogene
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7223397B1 (en) * 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
DE60137969D1 (de) * 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
DE60236450D1 (de) 2001-09-26 2010-07-01 Us Health Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
US20070196366A1 (en) 2003-04-30 2007-08-23 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
US7713737B2 (en) * 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US7611714B2 (en) 2004-10-04 2009-11-03 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
CA2941466C (en) 2005-07-29 2019-12-03 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Mutated pseudomonas exotoxins with reduced antigenicity
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
EP1966246A4 (de) * 2005-12-05 2010-01-06 Trinity Biosystems Inc Verfahren und zusammensetzungen zur nadellosen verabreichung von antikörpern
WO2007109110A2 (en) 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
EP2046375B1 (de) 2006-07-20 2017-04-05 The General Hospital Corporation Verfahren und zusammensetzungen zur selektiven aktivierung von protoxinen durch kombinatorisches targeting
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
JP2010534061A (ja) * 2007-07-20 2010-11-04 ザ ジェネラル ホスピタル コーポレイション 組換えコレラ菌外毒素
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
AU2010292069B2 (en) 2009-09-11 2015-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Improved Pseudomonas Exotoxin A with reduced immunogenicity
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
CN104689314B (zh) 2010-06-16 2018-02-02 高等教育联邦系统-匹兹堡大学 内质蛋白的抗体及其用途
SG10201506030RA (en) 2010-07-30 2015-09-29 Medimmune Llc Method for purifying active polypeptides or immunoconjugates
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2012036746A1 (en) 2010-09-15 2012-03-22 Randall J Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
ES2635416T3 (es) 2011-06-09 2017-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Exotoxina A de pseudomonas con epítopos de linfocitos T y/o linfocitos B menos inmunogénicos
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP2755993B1 (de) 2011-09-16 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
EP2764025B1 (de) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antikörper gegen hmw-maa
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
US9409992B2 (en) 2012-08-21 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
EP2900695B1 (de) 2012-09-27 2018-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin-antikörper und verfahren zur auslösung einer starken antitumoraktivität
EP3494992B1 (de) 2012-12-20 2022-07-27 Medimmune Limited Rückfaltung und reinigung von moxetumomab pasudotox
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
WO2015054691A2 (en) 2013-10-11 2015-04-16 The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services Tem8 antibodies and their use
EP3066118B1 (de) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
US10421958B2 (en) 2014-02-05 2019-09-24 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
RU2723178C2 (ru) 2014-05-07 2020-06-09 ЭППЛАЙД МОЛЕКЬЮЛАР ТРАНСПОРТ ЭлЭлСи Слитые молекулы, происходящие от Cholix-токсина, для пероральной доставки биологически активных нагрузок
EP3473271B1 (de) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Humane monoklonale antikörper gegen epha4 und deren verwendung
US10604582B2 (en) 2014-09-17 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health Anti-CD276 antibodies (B7H3)
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017049296A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
KR102776145B1 (ko) * 2015-11-13 2025-03-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-bcma 폴리펩티드 및 단백질
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
AU2017305170A1 (en) 2016-08-02 2019-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2017382883B2 (en) 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US11390683B2 (en) 2017-05-18 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
AU2018268970B2 (en) 2017-05-19 2024-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019055955A1 (en) 2017-09-18 2019-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN
HUE059330T2 (hu) 2018-03-08 2022-11-28 Applied Molecular Transport Inc Toxinból származó bejuttatási konstrukciók orális beadásra
JP7459043B2 (ja) 2018-07-12 2024-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
US12012463B2 (en) 2018-08-08 2024-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
JP7487193B2 (ja) 2018-11-07 2024-05-20 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体
AU2020206308A1 (en) 2019-01-08 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
WO2020154150A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CA3142833A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
KR20220066056A (ko) 2019-08-16 2022-05-23 어플라이드 몰레큘라 트랜스포트 인크. 조성물, 제형, 및 인터루킨 제조 및 정제
CN119899265A (zh) 2019-10-22 2025-04-29 美国政府(由卫生和人类服务部的部长所代表) 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
EP4110823A1 (de) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
TW202231663A (zh) 2020-12-22 2022-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
EP4448566A1 (de) 2021-12-17 2024-10-23 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-mesothelin-polypeptide, proteine und chimäre antigenrezeptoren
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024104584A1 (en) 2022-11-17 2024-05-23 University Of Cape Town Deimmunized pseudomonas exotoxin a
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
WO1991009949A1 (en) * 1990-01-02 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Target-specific, cytotoxic, recombinant pseudomonas exotoxin

Also Published As

Publication number Publication date
JP2665827B2 (ja) 1997-10-22
JPH05502380A (ja) 1993-04-28
EP0531434B1 (de) 1999-07-14
US5705156A (en) 1998-01-06
DK0531434T3 (da) 2000-01-31
US5512658A (en) 1996-04-30
CA2082394A1 (en) 1991-11-12
AU646673B2 (en) 1994-03-03
EP0531434A4 (en) 1993-10-13
CA2082394C (en) 1999-07-20
WO1991018100A1 (en) 1991-11-28
AU7991891A (en) 1991-12-10
JPH08283293A (ja) 1996-10-29
ATE182175T1 (de) 1999-07-15
DE69131449T2 (de) 1999-11-25
EP0531434A1 (de) 1993-03-17
JP2946457B2 (ja) 1999-09-06

Similar Documents

Publication Publication Date Title
DE69131449D1 (de) Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
ATE154237T1 (de) Inhalationspulver enthaltend antistatisches hilfsmittel
FI95768C (fi) Emättimensisäinen antosysteemi
ATE337019T1 (de) Geladene lipide und deren verwendung
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
NO166267C (no) Konjugat av et maalsoekende biologisk aktivt molekyl og en forbindelse inneholdende spormerkende metall, samt diagnostisk preparat inneholdende konjugatet.
FI834320A0 (fi) Peptidfoereningar
UA65561A (en) Therapeutic agent for lymphatic tumors
MX9602806A (es) Derivados del 1,2,4-oxadiazol y su uso como parasiticidas para animales.
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
IT1290062B1 (it) Amminosolfoniluree ad attivita' erbicida
CO5080738A1 (es) Formulaciones para la proteccion de conjugados de peginter- feron alfa
ES462103A1 (es) Procedimiento para la preparacion del derivado yodurado de cloruro de benzalconio.
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
IT1240676B (it) Composizioni ad attivita' erbicida
NO985414L (no) Farmas÷ytiske formuleringer inneholdende kalium-, natrium- og trioksaprozin salt
MX9305523A (es) Composiciones quimoterapeuticas mejoradas frente a infecciones microbianas en peces, la reparacion y uso de las mismas.
ES2081144T3 (es) Amidas de aminoacidos substituidas.
ATE114466T1 (de) Iontophoreseverfahren und -zusammensetzung.
IL110187A0 (en) 10-Substituted 1,8-dihydroxy-9(10H) anthracenones and pharmaceutical compositions containing them
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
MD346G2 (ro) Picoliden-4-izonicotinoilhidrazona dihidrată cu activitate tuberculostatică
IT8321740A0 (it) Derivati dell'isoindolina e composizioni terapeutiche che li comprendono come principio attivo.